JP2009522578A5 - - Google Patents

Download PDF

Info

Publication number
JP2009522578A5
JP2009522578A5 JP2008549563A JP2008549563A JP2009522578A5 JP 2009522578 A5 JP2009522578 A5 JP 2009522578A5 JP 2008549563 A JP2008549563 A JP 2008549563A JP 2008549563 A JP2008549563 A JP 2008549563A JP 2009522578 A5 JP2009522578 A5 JP 2009522578A5
Authority
JP
Japan
Prior art keywords
patient
marker
determining
markers
ovarian cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008549563A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009522578A (ja
JP5221381B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/000216 external-priority patent/WO2007081768A2/en
Publication of JP2009522578A publication Critical patent/JP2009522578A/ja
Publication of JP2009522578A5 publication Critical patent/JP2009522578A5/ja
Application granted granted Critical
Publication of JP5221381B2 publication Critical patent/JP5221381B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008549563A 2006-01-04 2007-01-04 卵巣癌を判定するためのｈｅ４及び他の生化学マーカーの使用 Active JP5221381B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75613106P 2006-01-04 2006-01-04
US60/756,131 2006-01-04
PCT/US2007/000216 WO2007081768A2 (en) 2006-01-04 2007-01-04 Use of he4 and other biochemical markers for assessment of ovarian cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012226640A Division JP5711196B2 (ja) 2006-01-04 2012-10-12 卵巣癌を判定するためのｈｅ４及び他の生化学マーカーの使用

Publications (3)

Publication Number Publication Date
JP2009522578A JP2009522578A (ja) 2009-06-11
JP2009522578A5 true JP2009522578A5 (enExample) 2010-02-25
JP5221381B2 JP5221381B2 (ja) 2013-06-26

Family

ID=38256906

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008549562A Active JP5164855B2 (ja) 2006-01-04 2007-01-04 子宮内膜または子宮癌を評価するためのｈｅ４及びそのほかの生化学的マーカーの使用
JP2008549563A Active JP5221381B2 (ja) 2006-01-04 2007-01-04 卵巣癌を判定するためのｈｅ４及び他の生化学マーカーの使用
JP2012226640A Active JP5711196B2 (ja) 2006-01-04 2012-10-12 卵巣癌を判定するためのｈｅ４及び他の生化学マーカーの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008549562A Active JP5164855B2 (ja) 2006-01-04 2007-01-04 子宮内膜または子宮癌を評価するためのｈｅ４及びそのほかの生化学的マーカーの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012226640A Active JP5711196B2 (ja) 2006-01-04 2012-10-12 卵巣癌を判定するためのｈｅ４及び他の生化学マーカーの使用

Country Status (7)

Country Link
US (8) US20080020473A1 (enExample)
EP (6) EP2982761B1 (enExample)
JP (3) JP5164855B2 (enExample)
CN (3) CN101460630B (enExample)
ES (2) ES2650244T3 (enExample)
PL (1) PL2982761T3 (enExample)
WO (2) WO2007081768A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5731400A (en) * 1999-06-09 2000-12-28 Moltech Corporation Methods of preparing electrochemical cells
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
EP1877795A4 (en) * 2005-05-02 2010-04-28 Brigham & Womens Hospital DIAGNOSTIC PROFILE MANUFACTURE OF SERUM ANTIBODIES
EP2982761B1 (en) * 2006-01-04 2017-10-04 Fujirebio America, Inc. Use of he4 and other biochemical markers for assessment of endometrial and uterine cancers
BRPI0707249A2 (pt) * 2006-01-27 2011-04-26 Tripath Imaging Inc métodos para identificar pacientes com maior probabilidade de terem cáncer de ovário e composições para os mesmo
WO2008049239A1 (en) 2006-10-27 2008-05-02 Mount Sinai Hospital Endometrial biomarkers
CA2679696A1 (en) * 2007-03-09 2008-09-18 Tripath Imaging, Inc. He4 monoclonal antibodies and methods for their use
JP5144742B2 (ja) * 2007-03-29 2013-02-13 フジレビオ ダイアグノスティックス インコーポレイテッド 乳がんの評価のためのｈｅ４の使用
CN101377502A (zh) * 2007-08-31 2009-03-04 北京科美东雅生物技术有限公司 肿瘤相关抗原72-4化学发光免疫分析测定试剂盒及其制备方法
WO2009099561A2 (en) * 2008-01-31 2009-08-13 The Brigham And Womens' Hospital, Inc. Urinary ca125 peptides as biomarkers of ovarian cancer
WO2009145815A2 (en) * 2008-04-01 2009-12-03 The Brigham And Women's Hospital, Inc. Biomarkers of ovarian cancer
WO2012027631A2 (en) * 2010-08-26 2012-03-01 University Of Washington Through Its Center For Commercialization Methods for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells
ES2834617T3 (es) 2011-02-17 2021-06-18 Fujirebio Diagnostics Inc Composiciones y métodos de uso para la determinación de HE4a
CA2828119A1 (en) * 2011-02-24 2012-08-30 Vermillion, Inc. Biomarker panels, diagnostic methods and test kits for ovarian cancer
CN102735840B (zh) * 2011-04-13 2014-06-04 中国医学科学院肿瘤研究所 用于诊断或筛查卵巢癌的试剂
EP2717901A4 (en) * 2011-06-06 2015-01-21 Women And Infants Hospital Of Rhode Island HE4-BASED THERAPY FOR MALIGNINE DISEASES
DE102012205164B4 (de) 2012-03-29 2021-09-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Projektionsdisplay und Verfahren zur Projektion virtueller Bilder
CN103575902B (zh) * 2012-08-03 2015-07-29 河南生生医疗器械有限公司 一种时间分辨荧光法四项综合检测卵巢癌试剂盒及其应用
CN102890083B (zh) * 2012-09-28 2016-08-10 辽宁科骏生物有限公司 化学发光底物溶液和含其的试剂盒及应用其的检测方法
CN104655858B (zh) * 2015-03-12 2016-02-10 德迈基生物技术（北京）有限公司 定量检测人附睾分泌蛋白-4的荧光免疫层析试剂盒及其制备方法
EP3273974A4 (en) 2015-03-26 2018-11-07 Women and Infants Hospital of Rhode Island Inc. Therapy for malignant disease
RU2585959C1 (ru) * 2015-06-22 2016-06-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ дифференциальной диагностики асцитно-инфильтративной формы рака яичников и абдоминального туберкулёза
US10267802B2 (en) 2015-09-23 2019-04-23 The Board Of Trustees Of The Leland Stanford Junior University Methods of prognosis and diagnosis of ovarian cancer
RU2624508C1 (ru) * 2016-06-29 2017-07-04 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования длительности ремиссии у больных раком вульвы
EP3482205A1 (en) 2016-07-08 2019-05-15 H. Hoffnabb-La Roche Ag Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment
US20230159586A1 (en) 2020-04-21 2023-05-25 University Of Rochester Inhibitors of human epididymus protein 4
CN111781364B (zh) * 2020-08-25 2023-07-21 北京信诺卫康科技有限公司 Wnt7a和HE4联合用作早期卵巢癌生物标志物以及试剂盒
WO2022140116A1 (en) 2020-12-21 2022-06-30 Freenome Holdings, Inc. Markers for the early detection of colon cell proliferative disorders
WO2023195629A1 (ko) * 2022-04-08 2023-10-12 아주대학교산학협력단 He4 검출용 펩타이드 및 그 용도
WO2023195628A1 (ko) * 2022-04-08 2023-10-12 아주대학교산학협력단 Ca125 검출용 펩타이드 및 그 용도
CN120254284B (zh) * 2025-06-03 2025-08-22 杭州广科安德生物科技有限公司 一种用于预测子宫内膜癌复发或转移风险的生物标志物及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA1289880C (en) * 1985-12-06 1991-10-01 Jeffrey L. Winkelhake Anti-human ovarian cancer immunotoxins and methods of use thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US6998106B1 (en) * 1998-12-01 2006-02-14 Duke University Radioconjugation of internalizing antibodies
CA2369433A1 (en) 1999-02-26 2000-08-31 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
US6770445B1 (en) * 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
US20020182619A1 (en) * 2000-11-08 2002-12-05 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
DK1540010T3 (da) * 2002-08-06 2010-07-26 Univ Johns Hopkins Anvendelse af biomarkører til påvisning af ovariecancer
AU2003269968A1 (en) * 2002-08-16 2004-03-11 Clinical Microarrays, Inc. Substrates for isolating, reacting and microscopically analyzing materials
AU2003290773A1 (en) * 2003-02-05 2004-09-06 Ciphergen Biosystems, Inc. Non-invasive assessment of intra-amniotic environment
EP1633784B1 (en) * 2003-05-09 2011-07-13 Diadexus, Inc. Ovr110 antibody compositions and methods of use
CN1266475C (zh) * 2003-06-05 2006-07-26 马旭 一种用于诊断早期卵巢癌的四粘蛋白酶联免疫检测试剂盒
EP1723428A2 (en) * 2004-02-19 2006-11-22 Yale University Corporation Identification of cancer protein biomarkers using proteomic techniques
WO2005098446A2 (en) * 2004-03-31 2005-10-20 The Johns Hopkins University Biomarkers for ovarian cancer
US8486648B2 (en) * 2005-02-16 2013-07-16 Dana-Farber Cancer Institute, Inc. Methods of detecting ovarian cancer
US20070172902A1 (en) * 2005-06-22 2007-07-26 The Johns Hopkins University, a non-profit organization Biomarker for ovarian cancer
EP1910821B1 (en) * 2005-06-24 2013-02-20 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer
EP2982761B1 (en) * 2006-01-04 2017-10-04 Fujirebio America, Inc. Use of he4 and other biochemical markers for assessment of endometrial and uterine cancers

Similar Documents

Publication Publication Date Title
JP2009522578A5 (enExample)
Jia et al. Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic review with meta-analysis
Jin et al. SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma
Abel et al. Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment
Oh et al. Differential immunohistochemical profiles for distinguishing prostate carcinoma and urothelial carcinoma
WO2010065968A1 (en) Cancer detection markers
US11402381B2 (en) Methods of identifying an individual to be treated by chemotherapy based on cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) marker molecules and related uses
US10139412B2 (en) Semaphorin 3A as a diagnostic marker for urothelial cancer
CN102298053B (zh) 原发性肝细胞肝癌术后复发风险评估的组合抗体试剂盒
Park et al. Clinical significance of lymph node micrometastasis in stage I and II colon cancer
CN107561280A (zh) 一种预测乳腺癌复发的试剂盒
Provenzano et al. Differential expression of immunohistochemical markers in primary lung and breast cancers enriched for triple‐negative tumours
Chen et al. Survivin as a useful adjunct marker for the grading of papillary urothelial carcinoma
CN109735619A (zh) 与非小细胞肺癌预后相关的分子标志物及其应用
JP2011209101A (ja) ＣａｐＧをマーカーとする悪性腫瘍の予後予測検査方法
US20180292410A1 (en) Methods of detecting a relapse of a lung adenocarcinoma based on marker human epididymis protein 4 (he4) and related uses
Yokoi et al. Immunophenotypic profile as a predictor of prognosis in advanced ovarian carcinoma
Alrashidy et al. Immunohistochemical differentiation between urothelial papillomas and papillary neoplasms of low malignant potential of the urinary bladder
CN116593702B (zh) 一种肺癌的生物标志物以及诊断系统
Ding et al. 584P Two-year update of the prospective evaluation of ColonAiQ (PreC) study
Makkai-Popa et al. Corelation of lymphocytic infiltrates with the prognosis of recurrent colo-rectal cancer
Cherciu et al. Targeted Confocal Laser Endomicroscopy (CLE) for the Assessment of Putative Cancer Stem Cell Markers in Colorectal cancer-A Pilot Study
Cho et al. CDX-2 protein and mRNA expression in canine intestinal adenocarcinoma
Wu et al. Correlation Between Drug Sensitivity Profiles of Ex Vivo Expanded Circulating Tumor Cells and Clinical Treatment Response in Pancreatic Ductal Adenocarcinoma Patients
Maqbool et al. Assessment of Tumour Budding in Colorectal Adenocarcinomas